A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)

Table 2 Normal tissue dose-volume constraints and standardised contouring nomenclature

Organ	Standardised name	Parameter	Investigational treatment
Organ	Standardised name	Constraint	28Gy in 1#	48Gy in 4#/2wks
Normal Lungs		V5 < 1000 cc	66 % 7.4Gy	66 % 12.4Gy, (max 3.1Gy per fraction)
Heart	Heart	Maximum dose (0.03 cc) < 15 cc	22Gy	34 Gy, (max 8.5 Gy per fraction)
Heart	Heart	Maximum dose (0.03 cc) < 15 cc	16Gy	28 Gy, (max 7 Gy per fraction)
Oesophagus	Oesophagus	Maximum dose (0.03 cc)	15.4Gy	30Gy, (max 7.5Gy per fraction)
Spinal Cord	SpinalCord	Maximum dose (0.03 cc)	12Gy	20.8Gy, (max 5.2Gy per fraction)
Brachial plexus	BrachialPlexus	Maximum dose (0.03 cc)	15Gy	24Gy, (max 6Gy per fraction)
Skin (5 mm subcutis)	Skin	Maximum dose (0.03 cc) < 10 cc	26Gy	36 Gy, (max 9 Gy per fraction)
Skin (5 mm subcutis)	Skin	Maximum dose (0.03 cc) < 10 cc	23Gy	33.2 Gy, (max 8.3 Gy per fraction)
Chest wall^a	ChestWall	<70 cc	^b26Gy to full thickness	30Gy
Great Vessels	GreatVessel	Maximum Dose (0.03 cc)	30 Gy	49 Gy, (max 12.25 Gy per fraction
Liver	Liver	V20, V30	No constraint, but dose/volume parameters to be documented	No constraint, but dose/volume parameters to be documented

^aChest wall dose limit may be exceeded if rib structure lies close to or in contact with the PTV
^b26Gy isodose line should not cross full thickness of the chest wall structure
Definitions: Vx describes the volume that receives xGy, e.g. V5 < 66 % represents that the volume of specified OAR receiving 5 Gy shall be less than 66 %

ISSN: 1471-2407